Flosequinan: Difference between revisions
ce |
fix |
||
| Line 54: | Line 54: | ||
Boots initiated a clinical trial called PROFILE to see if the drug could be useful in a wider population. The study was terminated early in 1993 due to increased mortality in the drug arm of the trial; preliminary results were published in a conference abstract by the PI [[Milton Packer]] and others, which promised data and analysis would be forthcoming in a future paper, but as of 2001 no such paper had been published.<ref>{{cite journal|last1=van Veldhuisen|first1=DJ|last2=Poole-Wilson|first2=PA|title=The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.|journal=International journal of cardiology|date=August 2001|volume=80|issue=1|pages=19-27|pmid=11532543}}</ref> |
Boots initiated a clinical trial called PROFILE to see if the drug could be useful in a wider population. The study was terminated early in 1993 due to increased mortality in the drug arm of the trial; preliminary results were published in a conference abstract by the PI [[Milton Packer]] and others, which promised data and analysis would be forthcoming in a future paper, but as of 2001 no such paper had been published.<ref>{{cite journal|last1=van Veldhuisen|first1=DJ|last2=Poole-Wilson|first2=PA|title=The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.|journal=International journal of cardiology|date=August 2001|volume=80|issue=1|pages=19-27|pmid=11532543}}</ref> |
||
Boots withdrew it from the market in July 1993.<ref name=Independent/><ref>{{cite news|last1=Associated Press|title=Heart Failure Drug Manoplax Taken Off Market|url=http://www.apnewsarchive.com/1993/Heart-Failure-Drug-Manoplax-Taken-Off-Market/id-41d97c60a47c8e296bb592d042586dc2|work=AP News Archive|date=July 19, 1993}}</ref> |
|||
Boots withdrew it from the market in October 1993.<ref name=Independent/> |
|||
==References== |
==References== |
||
Revision as of 07:05, 6 August 2017
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H10FNO2S |
| Molar mass | 239.267 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Flosequinan is a quinolone vasodilator that was discovered and developed by Boots UK and was sold for about a year under the trade name Manoplax. It had been approved in 1992 in the US and UK to treat people with heart failure who could not tolerate ACE inhibitors or digitalis.[1]
Boots initiated a clinical trial called PROFILE to see if the drug could be useful in a wider population. The study was terminated early in 1993 due to increased mortality in the drug arm of the trial; preliminary results were published in a conference abstract by the PI Milton Packer and others, which promised data and analysis would be forthcoming in a future paper, but as of 2001 no such paper had been published.[2]
Boots withdrew it from the market in July 1993.[1][3]
References
- ^ a b Hosking, Patrick (25 July 1993). "Manoplax: from heart to heartbreak: With millions lost on its 'wonder". The Independent.
- ^ van Veldhuisen, DJ; Poole-Wilson, PA (August 2001). "The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure". International journal of cardiology. 80 (1): 19–27. PMID 11532543.
- ^ Associated Press (July 19, 1993). "Heart Failure Drug Manoplax Taken Off Market". AP News Archive.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |